Trial Profile
Phase II Single-Arm Study of ON 01910.Na by 2-hr Infusion in Patients With Recurring Platinum-Resistant Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2017
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 31 Dec 2011 Actual patient number is 1 as reported by ClinicalTrials.gov.
- 13 Jul 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 13 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.